Arbro Pharmaceuticals Private Limited

Arbro Pharmaceuticals Private Limited, established on June 28, 1985, is a privately held pharmaceutical company headquartered in New Delhi, India. The company operates under the Corporate Identification Number (CIN) U24232DL1985PTC021362 and is registered with the Registrar of Companies, Delhi. As of March 6, 2026, Arbro Pharmaceuticals has an authorized capital of ₹1.99 crore and a paid-up capital of ₹1.78 crore. The company employs approximately 369 professionals, reflecting its commitment to quality and innovation in the pharmaceutical sector. Arbro Pharmaceuticals specializes in the manufacturing and export of pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

Arbro Pharmaceuticals operates state-of-the-art manufacturing facilities in New Delhi, adhering to WHO-GMP standards. These facilities are equipped to produce a diverse range of pharmaceutical formulations, including tablets, capsules, dry syrups, oral powders, and oral liquids, catering to both human and veterinary segments. The company's manufacturing capabilities are complemented by its research and development (R&D) division, which focuses on product innovation and technology upgradation, thereby strengthening its position in the pharmaceutical industry.

The leadership team at Arbro Pharmaceuticals is headed by Managing Director Mr. Vijay Kumar Arora, who has been instrumental in the company's growth since its inception. Dr. Saurabh Arora serves as the Director, contributing to the company's strategic direction and expansion. Mr. Sunil Kumar Jaitly holds the position of Whole-Time Director, overseeing daily operations and ensuring compliance with industry standards. This leadership trio brings a wealth of experience and vision, driving Arbro Pharmaceuticals towards continued success in the global pharmaceutical market.

Arbro Pharmaceuticals has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully submitted numerous dossiers for regulatory approvals in these regions, demonstrating its commitment to meeting international standards. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, Arbro's proactive approach to regulatory affairs indicates a strategic focus on compliance and market access in these key markets.

Arbro Pharmaceuticals has strategically positioned itself in emerging markets across Africa, Latin America, and Southeast Asia. The company's dedication to providing high-quality, cost-effective medicines aligns with the healthcare needs of these regions. Arbro's WHO-GMP certified facilities and commitment to regulatory compliance enhance its credibility and facilitate market entry in these areas. The company's focus on product innovation and technology upgradation further strengthens its position in these emerging markets.

Arbro Pharmaceuticals' geographic strategy reflects a balanced approach to market diversification and risk management. The company's export portfolio, valued at $952,000 USD across 68 shipments, is concentrated in two therapeutic categories: Advanced Antibiotics (96.0%) and Respiratory & OTC (4.0%). This concentration indicates a strategic focus on high-demand therapeutic areas. However, the lack of diversification in product categories suggests potential exposure to market fluctuations within these segments. Arbro's expansion into emerging markets demonstrates a proactive approach to mitigating concentration risk and capitalizing on growth opportunities in diverse regions.

Specific details regarding Arbro Pharmaceuticals' FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's proactive approach to regulatory affairs, including the submission of numerous dossiers for regulatory approvals in various countries, suggests a commitment to meeting international standards. While the absence of publicly disclosed FDA approvals may limit immediate market access in the U.S., Arbro's focus on compliance and quality positions it well for future opportunities in this market.

Arbro Pharmaceuticals' manufacturing facilities are WHO-GMP certified, ensuring adherence to international quality standards. The company's commitment to quality is further demonstrated by its ISO 9001:2008 certification, reflecting a robust quality management system. While specific details regarding EU GMP certificates and EDQM status are not publicly disclosed, Arbro's WHO-GMP certification and ISO accreditation indicate a strong foundation in quality manufacturing practices.

Arbro Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's facilities are also accredited by the Export Inspection Council of India, reflecting adherence to export quality standards. Arbro's commitment to regulatory compliance is further evidenced by its WHO-GMP certification and ISO 9001:2008 accreditation, underscoring its dedication to maintaining high-quality manufacturing practices.

As of March 28, 2026, there are no publicly available records of FDA Form 483 observations, warning letters, or import alerts associated with Arbro Pharmaceuticals. The company's proactive approach to regulatory affairs, including the submission of numerous dossiers for regulatory approvals in various countries, suggests a commitment to compliance and quality. While specific details regarding recent regulatory actions are not publicly disclosed, Arbro's focus on maintaining high standards positions it well in the global pharmaceutical market.

Arbro Pharmaceuticals operates in a competitive landscape, focusing on therapeutic areas such as Advanced Antibiotics and Respiratory & OTC products. The company's export portfolio, valued at $952,000 USD across 68 shipments, is concentrated in these two categories, with Advanced Antibiotics comprising 96.0% and Respiratory & OTC products 4.0%. This concentration indicates a strategic focus on high-demand therapeutic areas. While specific market share data for competitors in these categories is not publicly available, Arbro's emphasis on quality manufacturing and regulatory compliance positions it as a strong player in these segments.

Arbro Pharmaceuticals' key differentiators include its commitment to quality, as evidenced by its WHO-GMP certification and ISO 9001:2008 accreditation. The company's diversified product portfolio, encompassing over 700 formulations across various therapeutic segments, demonstrates its capacity for innovation and adaptability. Arbro's integrated approach, combining manufacturing, R&D, and regulatory compliance, enables it to deliver comprehensive solutions to its clients. Additionally, the company's strategic focus on emerging markets reflects its proactive approach to growth and market diversification.

Arbro Pharmaceuticals' current strategic direction emphasizes the manufacturing of generic pharmaceutical formulations, with a strong focus on quality and regulatory compliance. The company's diversified product portfolio, including over 700 formulations across various therapeutic segments, indicates a commitment to addressing a broad spectrum of healthcare needs. Arbro's expansion into emerging markets demonstrates a proactive approach to growth and market diversification. Looking ahead, the company's focus on product innovation and technology upgradation positions it well for future opportunities in both domestic and international markets.

Arbro Pharmaceuticals has a track record of consistent export activity, with a total export value of $952,000 USD across 68 shipments. The company's portfolio is concentrated in two therapeutic categories: Advanced Antibiotics (96.0%) and Respiratory & OTC products (4.0%). This concentration indicates a strategic focus on high-demand therapeutic areas. Arbro's commitment to quality is demonstrated by its WHO-GMP certification and ISO 9001:2008 accreditation, reflecting adherence to international manufacturing standards. The company's proactive approach to regulatory affairs, including the submission of numerous dossiers for approvals in various countries, suggests reliability and a commitment to compliance.

Importers should verify the following certifications to ensure product quality and compliance:

• WHO-GMP Certification: Confirms adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO website or by contacting Arbro Pharmaceuticals directly.

• ISO 9001:2008 Certification: Indicates a robust quality management system. Verification can be done through the International Organization for Standardization (ISO) website or by contacting Arbro Pharmaceuticals directly.

• Export Inspection Council of India Accreditation: Ensures